Phase III study (JAVELIN) evaluating avelumab for advanced head and neck cancer to be terminated early

Decision follows advice from the trial's independent data monitoring committee, which found based on an interim analysis, that addition of avelumab to chemoradiotherapy (CRT) is unlikely to significantly prolong progression-free survival in this patient population, vs CRT alone.